<DOC>
	<DOCNO>NCT00903422</DOCNO>
	<brief_summary>This study evaluate safety tolerability eltrombopag treatment low platelet count adult subject advance myelodysplastic syndrome ( MDS ) , secondary acute myeloid leukemia MDS ( sAML/MDS ) , de novo AML relapse , refractory ineligible receive azacitidine , decitabine , intensive chemotherapy autologous/allogeneic stem cell transplantation . This placebo-controlled study patient receive study medication daily 6 month , time dose study medication may adjust base upon individual platelet count bone marrow blast count . All subject receive best standard care ( platelet transfusion , mild chemotherapy , cytokine , valproic acid , all-trans retinoic acid , ESAs G-CSF ) addition study medication . Subjects take placebo may allow crossover eltrombopag treatment clinically statistically significant improvement bone marrow blast count see subject treat eltrombopag .</brief_summary>
	<brief_title>Eltrombopag Treatment Thrombocytopenia Subjects With Advanced Myelodysplastic Syndrome ( MDS ) Secondary Acute Myeloid Leukemia After MDS ( sAML/MDS )</brief_title>
	<detailed_description>A double-blind , randomize , placebo-controlled phase I/II study evaluate safety tolerability eltrombopag olamine , thrombopoietin receptor agonist , administer 6 month oral tablet daily adult subject advance MDS , sAML/MDS , de novo AML . Study medication may increase 300 mg ( 150 mg maximum dose East Asian subject ) , base upon individual platelet count bone marrow blast count .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Adult subject ( 18 year age old ) advance MDS , sAML/MDS , de novo AML &gt; =10 % &lt; =50 % blast bone marrow . Peripheral blood blast change time suggestive highly proliferative disease ( judged investigator ) . Subjects must dependent regular platelet transfusion platelet count take within 4 week prior randomization &lt; 30 Gi/L . Subjects must relapse , refractory ineligible receive standard treatment option azacitidine decitabine must relapse , refractory ineligible receive intensive chemotherapy autologous/allogeneic stem cell transplantation . A subject may consider relapsed/refractory standard treatment discontinue due lack efficacy . For subject ineligible standard treatment , permissible start one standard treatment study medication Investigator considers subject becomes eligible course study . Prior therapy demethylating agent ( azacitidine decitabine ) , lenalidomide IL11 ( oprelvekin ) must complete least 4 week Day 1 ; antithymocyte/antilymphocyte globulin , intensive chemotherapy , autologous/allogeneic stem cell transplantation must complete least 2 month Day 1 . If subject must discontinue course therapy due lack efficacy , washout period list apply ( patient may screen randomize immediately eligibility criterion meet ) . Subjects must platelet count platelet transfusion data available period 4 week prior randomization . Subjects advance MDS , sAML/MDS , de novo AML must stable disease indicated doubling time peripheral blast count &gt; 7 day screen . During 4 week prior randomization , subject must baseline bone marrow examination include follow : cytomorphology confirm bone marrow blast 1050 % , cytogenetics ( provide prevalent abnormal clone ) , The result test require prior subject randomization . Supportive/palliative therapy cytokine ( except IL11 ; oprelvekin ) , valproic acid , alltrans retinoic acid mild chemotherapy allow part local SOC , provide therapy stable dose 4 week . If subject chooses discontinue therapy prior study entry , must complete 4 week prior enrollment study , unless therapy discontinue due lack efficacy . Erythropoiesisstimulating agent ( ESAs ) anemic subject granulocyte colonystimulating factor ( GCSF ) subject severe neutropenia recurrent infection allow study per accept standard . Subjects enter study ESAs GCSF continue dose schedule optimal dose study medication establish . ECOG Status 03 . Subject able understand comply protocol requirement instruction . Subject sign date informed consent . Prothrombin time ( PT/INR ) activate partial thromboplastin time ( aPTT ) must within 80 120 % normal range baseline . Adequate baseline organ function define criterion : total bilirubin ( except Gilbert 's Syndrome ) &lt; = 1.5xULN ALT AST &lt; = 3xULN creatinine &lt; = 2xULN albumin must lower limit normal ( LLN ) 20 % . Subject practice acceptable method contraception ( documented chart ) . Female subject ( female partner male subject ) must either nonchildbearing potential ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation postmenopausal &gt; 1 year ) , childbearing potential use 1 follow highly effective method contraception ( i.e. , Pearl Index &lt; 1.0 % ) 2 week prior administration study medication , throughout study , 28 day completion premature discontinuation study : Complete abstinence intercourse ; Intrauterine device ( IUD ) ; Two form barrier contraception ( diaphragm plus spermicide , male condom plus spermicide ) ; Male partner sterile prior entry study partner female ; Systemic contraceptive ( combine progesterone ) . Subjects diagnosis acute promyelocytic leukemia . History treatment cancer ( MDS , sAML/MDS , de novo AML ) systemic chemotherapy and/or radiotherapy within last 2 year . History treatment romiplostim TPOR agonists . Preexisting cardiovascular disease ( include congestive heart failure , New York Heart Association [ NYHA ] Grade III/IV ) , arrhythmia know increase risk thromboembolic event ( e.g . atrial fibrillation ) , subject QTc &gt; 450 msec ( QTc &gt; 480 msec subject Bundle Branch Block ) . Bone marrow fibrosis lead inability aspirate marrow assessment . Spleen size &gt; 14 cm ( length per ultrasound examination ) . Leukocytosis &gt; =25,000/uL prior Day 1 study medication . Female subject nurse pregnant ( positive serum urine Betahuman chorionic gonadotropin [ BhCG ] pregnancy test ) screen predose Day 1 . Current alcohol drug abuse . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Active uncontrolled infection . Subjects infect Hepatitis B , C Human Immunodeficiency Virus ( HIV ) . Subjects liver cirrhosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>de novo AML</keyword>
	<keyword>sAML/MDS</keyword>
	<keyword>Thrombopoietin</keyword>
	<keyword>secondary Acute Myeloid Leukemia MDS</keyword>
	<keyword>MDS</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Platelets</keyword>
	<keyword>TPO-R agonist</keyword>
	<keyword>Advanced Myelodysplastic Syndrome</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Thrombopoietin receptor agonist</keyword>
</DOC>